Development of C-terminal α-Synuclein Vaccine for Treatment and Prevention of Parkinson’s Disease and Other Synucleinopathies
Objective: Prothena is developing active vaccine candidates targeting α-synuclein (α-syn) epitopes shown in clinical and/or preclinical studies to disrupt synuclein pathology. These vaccines, which target…The anti-alpha-synuclein antibody Lu AF82422 was safe and well tolerated in a FIH-SAD study in healthy subjects and patients with PD
Objective: Evaluation of safety, tolerability, pharmacokinetics (PK) and target engagement (TE) in healthy subjects (HS) and patients with Parkinson’s disease (PD) following single ascending doses…Remote keyboard tapping: potential signatures of early motor dysfunction in isolated REM sleep behaviour disorder
Objective: To compare keyboard tapping performance in people with iRBD with controls. Background: The Distal Finger Tapping (DFT)1 test and BRadykineisa Akinesia Incoordination test (BRAIN)2…Differential proteomic analysis of plasma exosomes in Parkinson disease associated with mutations in the GBA gene
Objective: To identify the protein changes and to search the potential biomarkers of PD among GBA mutation carriers. Background: Mutations in the GBA gene encoding glucocerebrosidase enzyme are the…Intestinal microbial dysbiosis promotes prebiotic-reversible inflammation in Parkinson’s disease
Objective: To determine the functional effects of disrupted intestinal microbiota in Parkinson’s disease (PD), particularly the impacts of dysbiosis on inflammation, neuroprotective hormone secretion, and…Prevalence and distribution of disease-associated alpha-synuclein in a homeless population
Objective: To study the prevalence and distribution of pathological alpha-synuclein deposition, throughout the central and peripheral nervous systems, in a homeless population. Background: The homeless…Marker Progression and Sample Sizes Estimates for Trials in Prodromal Parkinson’s Disease: A Multicenter Study
Objective: To inform the design of randomized neuroprotective trials in prodromal Parkinson’s disease (PD) by assessing the progression of prodromal markers in idiopathic rapid eye…Relationship between cardiovascular autonomic failure and cognitive performance in the α-synucleinopathies: preliminary cross-sectional analysis of the NHSS registry
Objective: To compare cognitive performances of patients with α-synucleinopathies with or without cardiovascular dysautonomia. Background: Cardiovascular dysautonomia is a disabling non-motor feature of the α-synucleinopathies and may…Parkinson Progression Marker Initiative – New Science/New Cohorts
Objective: The Parkinson Progression Marker Initiative (PPMI) is expanding its cohorts and exploring additional biomarkers of PD progression to test hypotheses of the underlying molecular…Defining LRRK2-PD subsets based on olfactory function in the PPMI
Objective: A major goal of the Parkinson Progression Marker Initiative (PPMI) is to identify clinical and biomarker defined disease subsets that may demonstrate differing disease…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 18
- Next Page »